Aprea, a Sweden-based cancer therapy developer backed by healthcare provider Praktikertjänst Group, closed a €46m ($50m) series B round yesterday.
The round was co-led by venture capital firms Versant Ventures and 5AM Ventures, with participation from investment manager Sectoral Asset Management and venture capital firm HealthCap.
Founded in 2000, Aprea is working on therapeutics to treat cancer by targeting the tumour suppressor protein p53.
The financing will partly be used to advance its lead drug candidate, APR-246, which is set…
